GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fagron SA (OTCPK:ARSUF) » Definitions » Debt-to-Revenue

ARSUF (Fagron) Debt-to-Revenue : 0.43 (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Fagron Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Fagron's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $11.4 Mil. Fagron's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $388.9 Mil. Fagron's annualized Revenue for the quarter that ended in Jun. 2024 was $924.3 Mil. Fagron's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.43.


Fagron Debt-to-Revenue Historical Data

The historical data trend for Fagron's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fagron Debt-to-Revenue Chart

Fagron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.73 0.64 0.59 0.58 0.48

Fagron Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.64 0.56 0.52 0.47 0.43

Competitive Comparison of Fagron's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Fagron's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fagron's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fagron's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Fagron's Debt-to-Revenue falls into.



Fagron Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Fagron's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(10.554 + 389.384) / 832.051
=0.48

Fagron's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(11.44 + 388.888) / 924.314
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


Fagron Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fagron's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Fagron Business Description

Traded in Other Exchanges
Address
Fascinatio Boulevard 350, Rotterdam, ZH, NLD, 3065 WB
Fagron SA is a pharmaceutical compounding company operating in Belgium. It acts as a supplier of pharmaceutical care to hospitals, pharmacies, clinics, and patients across the world. The company also produces pharmaceutical raw materials, equipment, and supplies that are needed to prepare medication in the pharmacy. Its segments are namely Fagron Europe, Middle East and Africa (EMEA), Fagron North America, and Fagron Latin America. The majority of its revenue comes from Fagron North America.

Fagron Headlines

From GuruFocus

Q4 2021 Fagron NV Earnings Presentation Transcript

By GuruFocus Research 02-12-2024

Q4 2020 Fagron NV Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q2 2024 Fagron NV Earnings Call Transcript

By GuruFocus News 10-09-2024

Fagron NV At Capital Markets Day Transcript

By GuruFocus Research 02-12-2024

Q4 2023 Fagron NV Earnings Call Transcript

By GuruFocus Research 03-25-2024

Q3 2021 Fagron NV Trading Statement Call Transcript

By GuruFocus Research 02-12-2024

Q1 2020 Fagron NV Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q3 2023 Fagron NV Trading Statement Call Transcript

By GuruFocus Research 02-12-2024

Q3 2019 Fagron NV Corporate Sales Call Transcript

By GuruFocus Research 02-12-2024

Q3 2022 Fagron NV Trading Statement Call Transcript

By GuruFocus Research 02-12-2024